Experts Challenge OS as Gold Standard Endpoint in Cancer Drug Trials: PFS Gains Clinical Relevance
Key Insights
Leading oncologists argue that progression-free survival (search) (PFS) should be recognized as a valid clinical benefit measure in cancer (search) drug trials, challenging the traditional emphasis on overall survival (search).
The increasing complexity of cancer (search) treatment pathways, including multiple therapy lines and molecular targeting, makes overall survival (search) (OS) less reliable as a primary endpoint in clinical trials.
A landmark melanoma (search) study demonstrates how modern treatment options have weakened the correlation between PFS and OS, dropping from 0.96 to 0.55 in the targeted therapy era.
The oncology community is witnessing a pivotal shift in how clinical benefit is measured in cancer (search) drug trials, with experts calling for a reevaluation of overall survival (search) (OS) as the primary endpoint for drug approval decisions.
Dr. Maurie Markman, president of Medicine & Science at City of Hope (search) Atlanta, Chicago, and Phoenix, argues that denying clinical benefit solely based on the absence of OS improvement overlooks significant therapeutic advances and patient-centered outcomes.
The Evolution of Clinical Benefit Measures
The debate centers on whether progression-free survival (search) (PFS) should stand alongside OS as a legitimate measure of clinical benefit. As cancer (search) increasingly becomes a chronic condition, with patients living longer and having access to multiple treatment lines, the traditional reliance on OS as the definitive endpoint faces mounting challenges.
"There is a fundamental question within the oncology sphere as to who ultimately should decide and what process should be employed to determine clinical benefit," notes Dr. Markman. He emphasizes that patients, rather than regulators or academic pundits, should have a voice in determining whether improved PFS represents meaningful clinical benefit.
Challenges with Overall Survival as an Endpoint
Several factors complicate the use of OS as a primary endpoint:
- Extended survival times in modern cancer care
- Access to multiple subsequent treatment lines
- Crossover options in clinical trials
- Impact of molecular targeted therapies
- Influence of comorbidities on survival
- Availability of palliative interventions
The Melanoma Paradigm Shift
A compelling example comes from melanoma (search) research, which demonstrates the changing landscape of cancer (search) treatment. Early in the targeted therapy era, PFS showed a strong correlation with OS (correlation coefficient 0.96). However, as more effective treatments became available, this correlation significantly weakened (correlation coefficient 0.55), highlighting how post-trial treatments influence survival outcomes.
Quality of Life Considerations
The discussion extends to quality of life (QOL) measures, which, while important, present their own challenges in standardization and measurement. Dr. Markman questions the feasibility of establishing universal QOL metrics that would satisfy regulatory requirements while meaningfully reflecting patient experiences.
Future Implications for Drug Development
While not dismissing the value of OS improvements, experts emphasize that failing to demonstrate OS benefits should not automatically disqualify drugs that show meaningful PFS improvements. This perspective has significant implications for drug development, regulatory approval processes, and ultimately, patient access to new therapies.
The evolving treatment landscape demands a more nuanced approach to evaluating cancer (search) drugs, one that considers both traditional endpoints and emerging measures of clinical benefit. This shift could fundamentally change how we develop and approve new cancer treatments, potentially accelerating patient access to innovative therapies.